key: cord-0874601-d1ge475q
authors: Zhou, Yaofeng; Wu, Yuhao; Ding, Lu; Huang, Xiaolin; Xiong, Yonghua
title: Point-of-care COVID-19 diagnostics powered by lateral flow assay
date: 2021-10-02
journal: Trends Analyt Chem
DOI: 10.1016/j.trac.2021.116452
sha: f5ae636fdc9679e4dc8ef2fc62663bda3bc09cc6
doc_id: 874601
cord_uid: d1ge475q

Since its first discovery in December 2019, the global coronavirus disease 2019 (COVID-19) pandemic caused by the novel coronavirus (SARS-CoV-2) has been posing a serious threat to human life and health. Diagnostic testing is critical for the control and management of the COVID-19 pandemic. In particular, diagnostic testing at the point of care (POC) has been widely accepted as part of the post restriction COVID-19 control strategy. Lateral flow assay (LFA) is a popular POC diagnostic platform that plays an important role in controlling the COVID-19 pandemic in industrialized countries and resource-limited settings. Numerous pioneering studies on the design and development of diverse LFA-based diagnostic technologies for the rapid diagnosis of COVID-19 have been done and reported by researchers. Hundreds of LFA-based diagnostic prototypes have sprung up, some of which have been developed into commercial test kits for the rapid diagnosis of COVID-19. In this review, we summarize the crucial role of rapid diagnostic tests using LFA in targeting SARS-CoV-2-specific RNA, antibodies, antigens, and whole virus. Then, we discuss the design principle and working mechanisms of these available LFA methods, emphasizing their clinical diagnostic efficiency. Ultimately, we elaborate the challenges of current LFA diagnostics for COVID-19 and highlight the need for continuous improvement in rapid diagnostic tests.

techniques [28] [29] [30] and biosensing strategies [31] [32] [33] [34] that have arisen in responding to 92 the recent COVID-19 pandemic [35] . To our best knowledge, a review paper focusing 93 on the critical role of LFA-assisted rapid diagnostic tests in managing COVID-19 94 remains missing. Herein, we provide the first systematic and comprehensive review of 95 emerging rapid diagnostic tests involving LFA techniques, and their application 96 potential to improve COVID-19 diagnosis by targeting SARS-COV-2-specific viral 97 RNA, antibodies, antigens, and whole viruses (Scheme 1). The key insights of the 98 reported LFA strategies on the design principle, working mechanism, methodological 99 performance, and clinical diagnostic efficiency are detailedly discussed. Additionally, 100 the status of commercially available LFA test kits for SARS-CoV-2 detection is 101 further summarized. The ending of this review will be organized to elaborate the 102 challenges and future improvements in COVID-19 diagnosis. quantitative information on viral loads in a highly sensitive and selective manner [40] . 115 However, the accessibility of rRT-qPCR in less-developed or remote regions largely 116 limits its broad appeal. In addition, this approach requires long testing time to give 117 result feedback, specialized laboratories, skilled technicians and expensive equipment 118 [41, 42] . Therefore, developing a series of simple and rapid POC nucleic acid testing 119 techniques is highly desired. The ability of LFA to sense nucleic acids in a rapid and 120 portable format has important applications ranging from field detection to clinical 121 diagnostics [43] . However, the SARS-CoV-2 concentration in specimen is very low 122 and hard to be directly detected using LFA [44] . Therefore, the integration of nucleic RPA introduced by GenDx Biotech (Fig. 1C) . In their study, a multienzyme RT-ERA IgA, and total antibodies to provide a guideline for LFIA development. to control the false positive rate at a targeted level [122] . (Fig. 3A) . In our design, after executing the conventional (Table 3) . 

Proc. Natl

1057 van den Akker